健择治疗难治性妇科癌症27例临床分析

A Clinical Study of Gemcitabine in the treatment of Patients with Refractory Genecological Cancer

目的 :研究健择治疗妇科癌症的临床疗效和毒副反应。方法 :采用健择单药或联合化疗治疗 7例宫颈癌和 2 0例上皮性卵巢癌 ,对疗效和毒副反应进行观察分析。结果 :2 7例健择化疗总有效率为 6 3 0 %,其中宫颈癌 85 7%、初治卵巢癌72 7%、复发性卵巢癌 33 3%。单药治疗有效率 40 0 %,联合治疗 6 8 2 %。中位缓解期 9个月。主要毒副反应为血液毒性 ,以白细胞下降为主 ,其中Ⅲ -Ⅳ级 11 8%,恢复较快。消化道反应、脱发、肝肾功能损伤、发热等均较轻。结论 :健择是治疗妇科癌症较安全且有一定疗效的抗癌药物 ,其联合用药可提高疗效 ,是治疗复发和耐药性卵巢癌较好药物之一。

Objective:To evaluate the clinical efficacy and toxicity of gemcitabine in refractory gynecological malignancies.Methods:7 patients with stage Ⅱ cervical cancer and 20 patients with advanced ovarian cancer were treated by single or combination gemcitabine chemotherapy. The clinical features were analyzed.Results:The total response rate was 63.0%, in which 85.7% for cervical cancer, 72.7% for primary ovarian cancer and 33.3% for recurrent and resistant ovarian cancer. The response rate treated by combination chemotherapy (68.2%) was higher than that treated by single. The media free-progress-period was 9 months. The main toxicity was hematological while non-hematological toxicity was mild and tolerable.Conclusion:Gemcitabine is effective in the treatment of gynecologic malignancies with modest side effects, and may be one of the better choices of recurrent and resistant ovarian cancer.